Sichenzia Ross Friedman Ference LLP Advises Sorrento Therapeutics, Inc. on $25.0 million Public Offering of Common Stock
NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, in a $25.0 million public offering. The offering consists of 4,765,000 shares of common stock priced at $5.25 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Jeff Fessler and Marcelle Balcombe.
- Sichenzia Ross Ference LLP代表Aegis Capital进行Farmmi，Inc.的4830万美元承销公开发行。 - May 3, 2021
- Sichenzia Ross Ference LLP在與私人配售有關的投資者訴訟中在第二巡迴上訴之前勝訴 - April 30, 2021
- Sichenzia Ross Ference LLP代表美国电池金属公司进行1,500万美元的注册直接发行 - April 29, 2021